Martin Shkreli is an American hedge fund manager and businessman. Shkreli is co-founder and former chief executive officer CEO of the biotechnology firm Retrophin, former CEO and founder of Turing Pharmaceuticals and co-founder of hedge funds Elea Capital thus people suspect that Shkreli's net worth is high as hell.
No doubt, Shkreli has a huge amount but what is the exact figure of his net worth sources and sources of his income? Today, we will be talking about her net worth, sources of income, and career details below:
How much is Martin Shkreli's net worth?
Martin Shkreli is the CEO of the start-up software company "Godel Systems" founded in August 2016. He is also the co-founder of the hedge funds MSMB Healthcare, Elea Capital, and MSMB Capital Management.
Shkreli is regarded as one of the youngest businessmen for all over the world. Sources claim that Shkreli's net worth is estimated to be around $50 million net worth. In another side, Martin Shkreli is estimated to collect around $70 million and now he claims that he has no cash left.
Martin Shkreli Source: vanityfair
Speaking of Shkreli's earnings, he earned around $6,359,300 in 2012 through Retrophin Pharma. In 2012, his net worth was estimated to be around $57,142,857. Following year, he collected around $7,843,137 and his net worth was around $80,000,000.
Martin Shkreli Source: nymag
In 2014, Shkreli collected $10,230,179 through Turing Pharma. He collected $86,956,522 net worth in 2014. In the year 2015, his total earnings were $11,764,706 and his net worth was estimated to be around $100,000,000.
Martin Shkreli Controversy: Drug Price Hike
Shkreli began Turing Pharmaceuticals in the year 2015. He obtained FDA approvals and licenses for the major expensive drugs within few months. In September 2015, Shkreli increased the price of HIV drug Daraprim from $13.50 to $750 per tablet.
The price highly increased and this result in problems in HIV treatments all over the country. It even resulted in irreparable harm to many patients. Shkreli faced a heavy criticism from several business tie-ups and medical associations, he resigned from Turing. Board chairman Ron Tilles replaced him.